Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
21 mars 2024 16h01 HE
|
Lyra Therapeutics
-- Data from ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Anticipated Q2 2024 -- WATERTOWN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc....
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 mars 2024 16h01 HE
|
Lyra Therapeutics
WATERTOWN, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting,...
Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
07 nov. 2023 16h01 HE
|
Lyra Therapeutics
– Additional Phase 2 BEACON trial CT scan data demonstrated statistically significant improvement in sinus opacification with LYR-220 and provided radiological evidence of improvement in chronic...
Lyra Therapeutics to Participate in Upcoming Investor Conferences
07 nov. 2023 07h00 HE
|
Lyra Therapeutics
WATERTOWN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of...
Lyra Therapeutics Announces Appointment of Ronan O’Brien as Chief Legal Officer
16 oct. 2023 07h00 HE
|
Lyra Therapeutics
WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the...
Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery
12 sept. 2023 07h00 HE
|
Lyra Therapeutics
Study demonstrates statistically significant and clinically relevant improvements in 3 Cardinal Symptoms and SNOT-22 scores at 24 weeks Statistically significant improvements in efficacy were...
Lyra Therapeutics to Participate in Upcoming Investor Conferences
06 sept. 2023 08h00 HE
|
Lyra Therapeutics
WATERTOWN, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of...
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
29 août 2023 07h00 HE
|
Lyra Therapeutics
WATERTOWN, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory...
Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
08 août 2023 16h01 HE
|
Lyra Therapeutics
-- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment in the Coming Weeks, with Data Expected in 1H 2024 -- -- Initial Topline...
Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference
13 juil. 2023 07h30 HE
|
Lyra Therapeutics
WATERTOWN, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of...